A study released in the journal JAMA Internal Medicine in February claimed to have found that GLP-1 based diabetes drugs increased a patient's risk of pancreatitis by 100%. Data from 2005 to 2008 were analyzed for Januvia from Merck (NYSE: MRK ) and Byetta from Bristol-Myers Squibb (NYSE: BMY ) . While that seemed to be bad news for GLP-1-based therapies (GLP-1 and DPP-4 classes), doctors and the Food and Drug Administration had been wary of such a link since 2007. It was simply the first time that a number had been put on the risk.
Well, things just got a lot more complicated. The European Medicine Agency's Committee for Medicinal Products for Human Use, or CHMP, initiated a study of its own and found no such link to an increased risk of pancreatitis. The EMA also found several flaws with the original JAMA study that could have led to a biased interpretation of the results. Will it change the mind of doctors and the FDA? Which companies stand to benefit? Fool contributor Maxx Chatsko breaks it down in the following video.
One of the best parts of owning big pharma stocks is their attractive dividends, but smart investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report "Secure Your Future With 9 Rock-Solid Dividend Stocks" outlines the Fool’s favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.